Ardena confirms spray drying upgrade and other capabilities at Spanish site
pharmafile | May 11, 2022 | News story | Research and Development |
Fully integrated Contract Development and Manufacturing Organisation (CDMO) has announced upgrades to its development and manufacturing facilities in Pamplona (Spain), with investments in dry granulation technology, and upgrades to its spray drying capabilities.
The company’s existing spray drying offering will be upgraded with ancillary equipment, allowing the company to manufacture inhaled drugs. The investments will allow the Pamplona site to handle a wider range of moisture-sensitive compounds, increase yields, and manufacture with a variety of organic solvents, like dichloromethane and chloroform.
“This investment allows us to develop drug formulations and manufacture clinical and small commercial batches with dry granulation. When added to our spray drying expertise, this means we can provide a wider range of formulation options to turn an amorphous solid dispersion into a finished dosage form in tablets or capsules,” said Ardena’s CEO, Harry Christiaens.
“Our scientific and technical capabilities in Pamplona allow us to work from formulation up to GMP manufacturing for clinical and commercial oral solid forms requiring solubility enhancement (BCS II and IV compounds with poor aqueous solubility), using spray drying as an established and scalable particle engineering technology, including all analytical methods and microbiological testing.
“Besides, we can handle highly potent compounds. This constitutes a distinctive combination in the CDMO market and something which our team is very proud of.”
Christiaens added: “We are delighted to welcome Stefano, who shares our science-led approach needed to deliver valuable, phase-appropriate, and integrated solutions for our biopharma customers globally. He is a recognised authority in the field of spray drying.”
Lina Adams
